Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L22 pseudogene 12 (RPL22P12) is a non-functional copy (pseudogene) of the gene encoding the human ribosomal protein L22. Pseudogenes like RPL22P12 typically arise from gene duplication or retrotransposition events and contain significant sequence similarity to their parent genes but do not produce a functional protein due to stop codons, frameshifts, or other mutations[4][5]. Although some ribosomal protein pseudogenes have been found to be transcribed, they generally do not have direct biological or therapeutic relevance and are not targeted by drugs or implicated as biomarkers[4][5]. RPL22P12 is part of a large family of ribosomal protein pseudogenes dispersed throughout the genome[5]. Key notes for curation: This gene is not a therapeutic target, receptor, or enzyme. It is categorized as a processed pseudogene based on sequence analysis. No evidence exists supporting a functional role, interaction with drugs, or disease association for RPL22P12 specifically. RPL22P12 should not be confused with the functional ribosomal protein L22 (RPL22), which is a genuine structural component of the ribosome[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L22 pseudogene 12 (RPL22P12).